News Snapshot:
(Bloomberg) -- Insilico Medicine, a Hong Kong-based company that uses artificial intelligence to drive drug discovery, filed confidentially for a U.S. initial public offering last week, according to people familiar with the matter. The Warburg Pincus-backed firm is working with advisers on the first-time share sale and is looking to raise around $300 million, the people said, asking not to be identified because the matter is private. Insilico was considering seeking a U.S. listing as soon as later this year, Bloomberg News reported in July. Deliberations are ongoing and the company could decide not to go ahead with the IPO,...
